Clinical psychologists Diana Naranjo and Korey Hood tackle the negative feedback loops that can develop around diabetes self-management and offer their insights on strategies to identify and address the roots of distress.
The results of the DECLARE-TIMI 58 trial show a broadly positive effect of dapagliflozin on cardiovascular outcomes, especially heart failure, in patients with type 2 diabetes.
Sodium-glucose cotransporter 2 inhibitors reduce the risk for heart failure hospitalization and renal disease progression in patients with type 2 diabetes regardless of existing cardiovascular disease, meta-analysis data show.
The results of the DECLARE-TIMI 58 trial show a broadly positive effect of dapagliflozin on cardiovascular outcomes, especially heart failure, in patients with type 2 diabetes.
Patients with type 1 diabetes may develop multiple complications even before they reach adulthood, shows an analysis of the SEARCH for Diabetes in Youth Study.
Source:
Lancet Child Adolesc Health 2018; doi:10.1016/S2352-4642(18)30309-2 Lancet Child Adolesc Health 2018; doi:10.1016/S2352-4642(18)30337-7
The novel, orally active vascular adhesion protein-1 inhibitor ASP8232 effectively reduces albuminuria, with few side effects, in patients with type 2 diabetes and chronic kidney disease, phase II study data show.
